Current Date 03 Apr, 2025
Wockhardt shifts US focus to novel antibiotics, exiting generics

Wockhardt shifts US focus to novel antibiotics, exiting generics

Wockhardt is focusing on developing new antibiotics in the US market, abandoning generics. Their novel antibiotic, Zaynich, shows promising results and seeks FDA approval. This strategy targets a large market vacated by Big Pharma, aiming for 10-year exclusivity. The shift aims to improve profitability and reduce dependence on the volatile US ge